Navigation Links
TB Drug Shortages Put U.S. Patients in Peril, Study Finds
Date:1/18/2013

THURSDAY, Jan. 17 (HealthDay News) -- Shortages of key tuberculosis drugs are posing a real hazard to patients throughout the United States, a new report finds.

The shortages are making it even more difficult to treat what's known as multidrug-resistant forms of the infectious respiratory illness, the researchers said. These patients often require so-called "second-line drugs" when the medication of choice fails.

For example, the new report cites the 2011 case of a father and his infant child who had each contracted TB. "Despite intensive efforts by public health personnel to obtain the two drugs [needed], the initiation of treatment was delayed by eight days for both patients, prolonging the father's infectious period and thereby increasing the risk for transmission to the community," wrote a team led by Dr. Barbara Seaworth of the University of Texas Health Science Center.

Matters were even worse for the baby, who had also contracted a form of meningitis and "was placed in a particularly dangerous situation," the researchers noted.

"TB meningitis in young children is a medical emergency, and delays in treatment lead to worse outcomes, such as severe [mental] impairment, epilepsy and death," according to the report published in the Jan. 18 issue of the Morbidity and Mortality Weekly Report, a journal of the U.S. Centers for Disease Control and Prevention.

In this case, both the father and baby did recover fully, but not every case involving drug shortages may turn out so well, the experts said.

In the new study, the National Tuberculosis Controllers Association surveyed TB programs across the United States and found that 81 percent of those that reported having patients with multidrug-resistant TB also said they had problems obtaining the medicines needed to treat these patients.

All of the programs that reported difficulties in obtaining drugs to treat multidrug-resistant TB listed nationwide shortages of the drugs as one of the reasons for the difficulties, according to the report.

In an accompanying editorial, experts noted that since September 2011, the supply of key second-line TB drugs has been "precarious."

"Kanamycin is no longer produced in the United States, streptomycin has been intermittently unavailable because of increased international demand, and capreomycin and amikacin have been available on an intermittent basis in only small amounts because of manufacturing problems and lack of raw materials," according to the editorial.

Other causes included shipping delays (noted in 71 percent of cases), lack of resources (62 percent), and the complicated process of obtaining certain drugs (48 percent).

As a result of difficulties obtaining drugs to treat multidrug-resistant TB, 58 percent of the TB programs reported delays in treating patients, 32 percent said there were lapses or interruptions in patient treatment, and 32 percent said they were forced to use an inadequate -- and potentially less effective -- treatment regimen.

Shortages disrupt the flow of care, as well, the editorial pointed out, leading to "rationing, increased drug costs, and inefficient use of staff time." They also "increase the risk for medication errors because regimens must be adjusted, leading to confusion over drug administration schedules, adverse reactions [side effects] and [drug-to-drug] interactions," the experts wrote.

Some efforts are underway to help ease the situation. In March of 2011, the Federal Advisory Council for the Elimination of Tuberculosis created a working group to address ongoing drug shortages, and in October 2011, a presidential order directed the U.S. Food and Drug Administration and the U.S. Department of Justice to fight drug shortages occurring across the health care spectrum.

"Reliable, consistent access to second-line drugs will require the collaboration of CDC, FDA, state and local health departments, national health professional societies, and the pharmaceutical industry," the study authors concluded.

More information

The American Lung Association has more about multidrug-resistant TB.

-- Robert Preidt

SOURCE: Jan. 18, 2013, Morbidity and Mortality Weekly Report


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Spot Shortages of Flu Vaccine, Tamiflu Reported, FDA Head Says
2. Fentanyl Injection Shortages Reported: Severe Adverse Events as AttorneyOne Informs
3. Canada needs national approach to protect against drug shortages
4. Researchers find that simple blood test can help identify trauma patients at greatest risk of death
5. 1,800 Michigan doctors launch effort to improve health care for Medicare patients
6. Chemo Pills Effective, But Patients May Skip Doses
7. Director of the Center for Craniofacial & Dental Sleep Medicine Provides New Cutting Edge Technology for Patients Suffering with Obstructive Sleep Apnea
8. COPD patients at risk of dangerous bacterial infections
9. Physical Therapists Now Have A Powerful Adjunct To Their Therapy Plan With The New Rehab In Motion™ Program Designed For Patients Who Have Limited Or No Health Insurance
10. Obese Patients May Have Less Success With Back Surgery
11. Doctors Often Miss Signs of Problem Drinking in Patients, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
TB Drug Shortages Put U.S. Patients in Peril, Study Finds
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: